Ascendis将在ISDS 2026大会上口头报告Transcon® CNP(Navepegritide)关键试验第104周数据

投资观察
Aug 26

8月25日(路透社)——Ascendis Pharma A/S宣布,其将在ISDS 2026会议上,就Transcon® CNP(Navepegritide)关键性试验的第104周数据,进行口头报告。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10